Findings {#Sec1}
========

Background {#Sec2}
----------

Endogenous endophthalmitis in the pediatric population is rare and is usually associated with poor visual outcomes. Endogenous endophthalmitis in neonates constitutes 0.1% to 4% of all endogenous endophthalmitis cases \[[@CR1]-[@CR3]\], with the highest incidence of cases reported in India and the lowest in the United States. Gram-positive organisms are causative in 30% to 35% of endogenous endophthalmitis \[[@CR4],[@CR5]\]. Potential risk factors \[[@CR6],[@CR7]\] for neonatal endogenous endophthalmitis are immune-compromised status, low birth weight (\<1,500 g), bacteremia, prematurity, blood transfusion, respiratory infection, perinatal infection, hospital admission, intravenous catheters, and retinopathy of prematurity. Vancomycin resistance among enterococci, coagulase-negative *Staphylococci*, and *Bacillus* is being increasingly reported \[[@CR8]\] in ocular infections. Herein, we report bilateral endogenous endophthalmitis due to multidrug-resistant gram-positive cocci in a neonate of age 18 days.

Case report {#Sec3}
-----------

An 18-day full-term male baby, born by normal vaginal delivery in rural India, presented with redness in the left eye for 1 day. There was no history of maternal fever, vaginal purulent discharge, or any complication before, during, or after birth. On initial examination, the child looked active, the right eye lacked a red reflex, and the left eye exhibited leukocoria. Echography showed an attached retina in both eyes without any evidence of intraocular calcification or mass lesion (Figure [1](#Fig1){ref-type="fig"}a,b). The left eye exhibited moderate-intensity opacities diffusely in the vitreous cavity. Computed tomography scan of the orbits could not be obtained due to financial limitation. On the day of presentation, after discussing the possibility of intraocular malignancy with the parents and obtaining written informed consent, the child was examined under anesthesia. The right eye had a clear cornea, well-formed anterior chamber, non-dilating pupil, iris vascular congestion, clear lens, and vitritis with no fundus view (Figure [1](#Fig1){ref-type="fig"}c). In the left eye, conjunctival congestion (deep and diffuse) was seen with diffuse corneal edema obscuring all further details (Figure [1](#Fig1){ref-type="fig"}d). A diagnosis of endogenous endophthalmitis was made. In the left eye, the anterior chamber was irrigated with saline through a single limbal paracentesis but it did not alter the corneal appearance which remained opaque white. A vitreous biopsy could only be performed in the left eye with a 23 G vitreous cutter at 0.5 mm from the limbus because of no view to the posterior segment. The sclerotomy port was sutured with 7-0 vicryl suture. Intravitreal antibiotics (vancomycin 0.5 mg/.05 ml + ceftazidime 1 mg/0.05 ml) and dexamethasone (200 μg/0.05 ml) were injected in both eyes with separate 29 G needles at 0.5 mm from the limbus since there were no fungal filaments on smear evaluation of the vitreous. Details of treatment are mentioned in Table [1](#Tab1){ref-type="table"}.Figure 1**Ultrasound B-scan and clinical photographs of both eyes taken under operating microscope at presentation.** Ultrasound B-scan shows attached retina in both eyes with clear vitreous cavity in the right eye **(a)** and echogenic shadows in the left vitreous cavity **(b)**. Clinical photographs taken under operating microscope shows clear cornea in the right eye **(c)** and diffuse circumciliary congestion with opaque cornea obscuring any further details in the left eye **(d)**.Table 1**Treatment details of the patientDay of presentation (age in days)Events**1 (18th day of life)Surgical treatmentLeft eye - anterior chamber wash + vitreous biopsyBoth eyes - IOAB (V + C + D)^a^Topical treatment in both eyes - ciprofloxacin 0.3% four times a day, prednisolone acetate 1% every 3 h, and atropine 1% eye ointment at nighttime^b^Systemic treatment - intravenous cefpodoxime by a pediatrician^c^3 (21st day of life)Both eyes - IOAB (V + C + D)^a^8 (26th day of life)Both eyes - IOAB (P/T + D)^d^13 (31st day of life)Left eye - IOAB (P/T + D)^da^IOAB (V + C + D) - intravitreal antibiotics (vancomycin 0.5 mg/.05 ml + ceftazidime 1 mg/0.05 ml) and dexamethasone (200 μg/0.05 ml); ^b^topical antibiotics were continued for 8 weeks (until resolution of all active inflammation); ^c^systemic antibiotics were given for 3 weeks; ^d^IOAB (P/T + D) - intravitreal antibiotics \[piperacillin- tazobactam (112.5 μg/0.05 ml)\] and dexamethasone (200 μg/0.05 ml).

Vitreous biopsy was negative for any growth while the blood culture showed gram-positive organisms (*Staphylococcus epidermidis*) which were resistant to vancomycin, amoxicillin, kanamycin, cephalothin, and erythromycin by the Kirby-Bauer disk diffusion method. Urine cultures of the neonate and the mother and culture of a vaginal swab of the mother showed no growth. The isolates were sensitive to piperacillin-tazobactam (112.5 μg/0.05 ml) which was administered intravitreally as mentioned in Table [1](#Tab1){ref-type="table"}. In the subsequent week, the child's right pupil was mid-dilated with a good view of the disk and macula while the left cornea continued to be opaque with decreased signs of ocular inflammation.

At 12 months of follow-up (Figure [2](#Fig2){ref-type="fig"}), no active inflammation was seen in either eye. The right eye fixed and followed light. The corneal whitening in the left eye has resolved. Twenty one months after presentation, cataract surgery was performed on the left eye due to subsequent cataract formation. At the 2-year follow-up, the right eye has good visual function with fix-and-follow vision and a good view of the posterior segment. The left eye is pseudophakic with a good red reflex and has a clear cornea.Figure 2**Clinical picture showing resolved endophthalmitis with clear corneal reflex in both eyes at 1 year follow-up.**

Discussion {#Sec4}
----------

Vancomycin resistance among gram-positive bacterial endophthalmitis has become a major global health issue \[[@CR9]\]. Vancomycin - a glycopeptide - is the drug of choice for methicillin-resistant coagulase-negative *Staphylococcus* and methicillin-resistant *Staphylococcus aureus* (MRSA) infections \[[@CR10],[@CR11]\]. Biofilm formation \[[@CR12]\] and alteration of binding sites of drug \[[@CR13]\] are the mechanisms of acquiring resistance to vancomycin. These resistant traits are then selected for in the presence of vancomycin. The Endophthalmitis Vitrectomy Study in 1996 reported the vancomycin sensitivity of gram-positive organisms to be 100%. A few reports of vancomycin resistance among *Bacillus*, *Enterococcus*, and *Staphylococcus* species causing endophthalmitis have been published recently \[[@CR11],[@CR13],[@CR14]\]. In this patient, the organism was sensitive to piperacillin-tazobactam, cefotaxime, doxycycline, clarithromycin, cefixime, and gentamycin. Piperacillin-tazobactam is a combination of beta-lactam antibiotic with beta-lactamase inhibitor in a ratio of 8:1 (piperacillin/tazobactam) and has broad antibacterial activity against gram-positive and gram-negative pathogens \[[@CR9],[@CR15]\]. Endogenous endophthalmitis is associated with poor anatomical and visual outcomes. In a study of 26 neonates \[[@CR6]\] with endogenous endophthalmitis, 22 out of 26 cases (84.61%) became phthisical. Khera et al. \[[@CR13]\] reported a single case of endogenous endophthalmitis, caused by vancomycin-resistant gram-positive cocci, in an adolescent resulting in enucleation. In our case, the child had a better outcome with complete resolution of endophthalmitis in both eyes and achieved fixing and following in the right eye. Maternal infections, sepsis during childbirth, low birth weight, etc. are the reported predisposing factors for neonatal endogenous endophthalmitis. In the present case, detailed history (both mother and child) did not reveal the predisposing factor. The fact that the child was born by a vaginal delivery in the rural India may raise the possibility of infection in perinatal or postnatal period.

In this case, no immunological workup to rule out impaired immunity was done. However, the child responded to the antibiotics well without any further recurrence or disease. Another limitation was that antibiotic resistance was assayed by disk diffusion only and not by minimum inhibitory concentration (MIC) because this assay was not available. Additionally, cultures were positive only from blood and not intraocular fluid; however, the subsequent response to treatment supports our clinical impression that the child's bacteremia was the cause of endophthalmitis, implicating multidrug-resistant *S. epidermidis* as the target pathogen. To the best of our knowledge, this is the first reported case of vancomycin-resistant bilateral endogenous endophthalmitis in a neonate with good outcomes. This report emphasizes the need of early management including intravitreal antibiotics guided by culture sensitivities which can result in a favorable outcome.

Conclusion {#Sec5}
----------

In conclusion, early recognition of antibiotic resistance and treatment with appropriate antibiotics (as in our case with piperacillin-tazobactam) were associated with resolution of infection. Ocular and extraocular culture and sensitivities should be obtained as early as possible to isolate the causative organism and best chose an appropriate therapy. Appropriate early intervention can result in favorable outcome.

Consent {#Sec6}
=======

The written informed consent from the parents of child was taken before initiating the treatment. IRB of our institute does not require approval to write case report up to 3 cases.

IOAB (V + C + D)

:   Intravitreal antibiotics (vancomycin + ceftazidime + dexamethasone)

IOAB (P/T + D)

:   Intravitreal antibiotics (piperacillin-tazobactam + dexamethasone)
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